John Smith (@slicktrader007) profile picture
Joined September 2016
$CAPR If the @FDA thinks deramiocel doesn't work, say so and show why. If the real problem is the timing of the SAP revisions, that's a terrible reason to leave DMD kids with nothing. Families gave a year of placebo for this data & lost a year of function they can't recover.
1
2
34
$CAPR At the AdCom, FDA's own stat chief John Scott said the imputation issue is "more of a robustness question than a prespecification question" Capricor then ran 600+ robustness analyses, most favoring deramiocel. CRL anyway, with no public reason why that analysis was ignored
1
1
5
230
Was $CAPR set up to fail? An RMAT therapy, yet a 2022 draft surfaced as the benchmark days before the AdCom, a vote on the wrong indication, a 2025 AdCom quietly pulled day before publication, 13 meetings refused. Congress and the HHS Inspector General should be asking FDA why.
1
1
10
328
$CAPR All we're askng for is transparency frm both sides.FDA & Capricor should each show their cards:the CRL, the inspection findings the data & the timeline behind their claims.Whoever is shown to be wrong should face real consequences.The DMD community deserves the full record
2
29
659
$CAPR @RogerMarshallMD @SenRonJohnson FDA turned down deramiocel over disputes about analysis plans & trial procedure. Not safety. Not a failed trial.Meanwhile Duchenne boys keep losing arm funct they'll never get back. When process outranks patients, the system has failed them
Replying to @slicktrader007
*8 years* My son’s trial date started October 2018. Was placebo first year. 4 agonizing treatments, sometimes took 8 sticks to get the needle in his arm. We knew he wasn’t getting the medicine (it was obvious), waited thru the pause. 1st treatment, he felt it after 12 days. His stamina increased, his upper body strength increased (PUL). Second treatment - needle went in 1st try - his tissue was now holding his veins in place. It gave him hope, it gave him at least a decade of life he would not have had. He no longer gets bronchitis 2x per year. His allergies went away. His arm strength is waning, but his LEVF is 60%. At age 24. Living with Duchenne. Normal heart function. The FDA has lost their minds, never had any brains, or is bought out by big pharma. The panel is choosing to deny based on what amounts to scientific semantics. BOTH the FDA and Capricor made mistakes thru this trial. I fail to see why my son should die faster because of their petty grievances.
1
2
27
877
$CAPR If Capricor did something wrong, it should answer for it. But FDA has to show its work too. Unblinding was only ever inferred, never shown. And by FDA's own definition at the AdCom, nothing in SAP 3.0 or earlier is "post hoc." Publish the CRL and the inspection findings.
17
592
$CAPR FDAs statement alleges data integrity violations but hasn't shown its evidence publicly.Capricor says it stands behind "the integrity of our data." Expect a fight.Publish the CRL and the inspection findings, & let the Duchenne community see exactly what this was decided on
8
327
$CAPR The blood is on the hands of the @FDA and its broken leadership. All the talk of a rare disease framework and regulatory flexibility means nothing. The biostatisticians can celebrate. They failed to see what the patients testified to and what the Lancet and AHA recognized
$CAPR @FDA got its procedural win.The Duchenne community got nothing.Boys who spent yrs in this trial, families who testified,a disease wth no othr option for these patients.Every month of appeal or a new trial is arm function they wont get back.That cost belongs in the decision
1
14
738
$CAPR @FDA got its procedural win.The Duchenne community got nothing.Boys who spent yrs in this trial, families who testified,a disease wth no othr option for these patients.Every month of appeal or a new trial is arm function they wont get back.That cost belongs in the decision
1
1
26
1,863
$CAPR Some of these boys have stayed in Capricor's extension study for over 5 years. Families don't give up years of infusions and clinic visits for a drug they think does nothing. Their time, their hope, their testimony deserved more than a CRL. My heart is with them tonight.
3
3
59
2,405
$CAPR The Duchenne community wasnt well served tonite.A +ve randomized trial in 106 boys, a clean safety rec, the Lancet, families' testimony, 28 investigators. FDA cites data integrity. Capricor says it stands behind its data.These boys deserve that fight settled fast & in open
9
513
$CAPR Elevidys got through on a failed primary with a handful of non-ambulatory patients. Deramiocel, 106 boys in the hardest population and a clean safety record, gets a CRL. The Duchenne community deserves consistency. Publish the CRL and let the evidence be judged in the open
2
4
25
1,614
$CAPR @FDADrugs @RobertKennedyJr @FDA_KyleD Time to walk the talk on the rare disease framework. These kids have waited long enough, and time isn't on their side. Remember: "The absence of treatment is not the absence of harm."
It's World Children's Day. How historic would it be for the @FDADrugs to approve $CAPR today and give kids with Duchenne the treatment option they deserve? No better day to put children first. Duchenne families have waited long enough. #WorldChildrensDay #UniversalChildrensDay
14
787
It's World Children's Day. How historic would it be for the @FDADrugs to approve $CAPR today and give kids with Duchenne the treatment option they deserve? No better day to put children first. Duchenne families have waited long enough. #WorldChildrensDay #UniversalChildrensDay
3
2
1
32
2,086
$CAPR At the AdCom, FDA said HOPE-3 was powered to detect 1.5 PUL points. That number came from an early 2022 draft written for a 68-patient trial. The trial that actually ran enrolled 106 and was powered for 1.1 points. HOPE-3 was graded against a study that never happened. @FDA
9
985
fixes: $CAPR Let's see the @FDA actually walk the talk. There are a lot of kids in dire need of treatment, waiting with bated breath for the 11/22 PDUFA decision. @realRFKJr
RFK Jr. says children with rare diseases are losing their lives while waiting for doctors to figure out what’s wrong. He says it takes an average of 6 YEARS to diagnose these diseases, while nearly 30% of affected children die before their 5th birthday. “1 out of every 10 American children has a rare disease.” “Today, we have about 10,000 rare diseases that we know about, and only about 5% of those have treatments.” “And so there’s an entire cohort of kids with almost 10% of our population that has no available treatment.” “You can, in some cases, treat the symptoms even though you can’t treat the disease or cure the disease.” “But it’s very important to catch them early.” “And on average, about 30% of those kids die before they’re age 5.” “And on average, it takes 6 years to diagnose.” “So we’re losing those kids because of our incapacity to diagnose them.” @The_MAHA_Center
1
36
1,590
$CAPR At the AdCom, panel statistician Janet Wittes asked FDA: "Is post hoc 1.1, or is it two, or is it three?" And: "If I had to finalize a SAP before the data collection, every study I've been involved in would be thrown out." Coffey questioned SAP 1.1 as the benchmark too.
15
1,006
$CAPR FDA called SAP 3.0 "post hoc" for hours. Its own statistician later defined post hoc as changes after 3.0, & said the imputation was "more of a robustness question." The investigators'letter: "By then the damage to the Committee's view of the upper-limb data…had been done
13
947
$CAPR Worried the model was tuned? A randomization test reshuffled HOPE-3's treatment labels 20,000 times with no model at all. p ≈ 0.03, vs 0.029 from the filed model. The result doesn't come from the math chosen. #Robustness
8
774
$CAPR 28 investigators who ran HOPE-3, with more deramiocel experience than any physicians anywhere, say it slows upper limb loss. They also wrote that a new 12–18 month placebo trial in advanced DMD would be unethical. That's a strong statement from clinicians, not the company.
3
20
1,137